



JPW

PATENT
Attorney Docket No: 053893-5047-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: James A. HOXIE

Application No.: 10/829,475

Group Art Unit: 1648

Filed: April 22, 2004

Examiner: not yet assigned

For: ANTIBODIES DIRECTED AGAINST CELLULAR CORECEPTORS FOR HUMAN
IMMUNODEFICIENCY VIRUS AND METHOD OF USING THE SAME

Commissioner for Patents
U.S. Patent and Trademark Office
Arlington, VA 22202

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

There is an error with respect to the following data which is incorrectly entered:

Section That Error Is In: Domestic Priority data as claimed by applicant

Correct Data

This application is a REI of 08/882,435 06/25/1997 PAT 5,994,515
which claims benefit of 60/020,396 06/25/1996
and claims benefit of 60/020,647 06/27/96

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

By: *Erich E. Veitenheimer*
Erich E. Veitenheimer
Reg. No. 40,420

Dated: November 12, 2004

Customer No. 009629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
(202)739-3000


KID
PNK
EEV

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/829,475	04/22/2004	1648	450	053893-5047-01	14	7	1

009629
MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004



CONFIRMATION NO. 5881
UPDATED FILING RECEIPT
OC000000014265150
OC000000014265150

Date Mailed: 11/02/2004

Receipt is acknowledged of this reissue Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

James A. Hoxie, Berwyn, PA;

Power of Attorney: The patent practitioners associated with Customer Number **009629**.

Domestic Priority data as claimed by applicant

This application is a REI of 08/882,435 06/25/1997 PAT 5,994,515
which claims benefit of 60/020,396 06/25/1996
and claims benefit of ~~60/021,301 07/08/1996~~

60/020,477 06/27/96

Foreign Applications

If Required, Foreign Filing License Granted: 06/13/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/829,475**

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

NOV 01 2004
MORGAN LEWIS & BOCKIUS LLP

DOCKETED
By Date 11/4/04

**** SMALL ENTITY ******Title**

Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same

Preliminary Class

530

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).